ArticlePloS one2025
Weifuchun alleviates MNNG-induced chronic atrophic gastritis by improving the gastric and intestinal microbiota homeostasis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanism of Lian-Huo-Hua-Zhuo Formula in Alleviating Gastric Mucosal Inflammation in a Mouse Model of Chronic Atrophic Gastritis by Inhibiting the IL-17 Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic atrophic gastritis (CAG) is a prevalent condition that can undergo precancerous lesions of gastric cancer (PLGC) and thus progression to gastric cancer. Weifuchun (WFC), a traditional Chinese herbal compound, is employed in CAG treatment and microbial homeostasis modulation. We aimed to explore the role of WFC in CAG from the perspective of gastrointestinal microbiota.
methodsPLGC rats were developed by N-methyl-N'-nitro-N-nitrosoguanidine treatment. Then, various doses of WFC were administered to the rats and WFC compositions were analyzed. The pathological changes and inflammatory markers of the rats were assessed. Key proteins in the interleukin (IL)-6/Janus Kinase 1/Signal Transducer and Activator of Transcription 3 (JAK1/STAT3) pathway were evaluated, alongside fecal microbial analysis through 16S ribosomal DNA sequencing.
resultsMost compounds identified from WFC were nucleosides, flavones, organic acids, phenylpropanoids and other components. WFC treatment alleviated intestinal metaplasia and dysplasia caused by atrophic gastritis in PLGC rats. WFC also reduced inflammatory marker levels, and inhibited the IL-6/JAK1/STAT3 pathway for PLGC rats. The higher the dose of WFC was administrated, the better the effects on the aforementioned results. Simultaneously, WFC improved the CAG gastrointestinal microbiota homeostasis. Interestingly, WFC increased Coprocuccus abundance, which was significantly correlated with proliferating cell nuclear antigen and IL-6 levels.
conclusionsWFC alleviated PLGC by regulating the balance of gastrointestinal microbiota and influencing the IL-6/JAK1/STAT3 pathway, revealing the potential connection between gastrointestinal microbiota and CAG progression. This study is the first to link gastrointestinal microbiota homeostasis and IL-6/JAK1/STAT3 pathway, providing novel insights into WFC's multi-targeted therapeutic mechanism on CAG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.